AF
ELTX icon

Amalgamated Financial’s Elicio Therapeutics ELTX Stock Holding History

Amalgamated Financial’s Portfolio ELTX Stock Details ELTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		$8K Buy
+373
New +$8.42K ﹤0.01% 2926

Other funds holding ELTX

NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CM
CM Management Gulf Breeze, Florida $120M AUM 37.12% 1-Year Est. Return
LSAG
Lake Street Advisors Group Portsmouth, New Hampshire $2.17B AUM 16.99% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Amalgamated Financial's ELTX Position: Q1 2022 in Review

Amalgamated Financial opened a new position in Elicio Therapeutics (ELTX) in Q1 2022: 373 shares worth $8K. The stake represents ﹤0.01% of the portfolio and ranks #2926 among its holdings.

47 funds tracked by Wall St. Rank hold ELTX as of Q1 2022.

  • Amalgamated Financial held 373 shares of Elicio Therapeutics worth $8K as of Q1 2022.
  • Elicio Therapeutics was a new Amalgamated Financial position in Q1 2022.
  • Elicio Therapeutics made up ﹤0.01% of Amalgamated Financial's portfolio in Q1 2022, its #2926 holding.
  • 47 funds tracked by Wall St. Rank held Elicio Therapeutics as of Q1 2022.

Based on Amalgamated Financial's 13F filing for Q1 2022, filed 16 May 2022.